Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
iShares Biotechnology ETF
(NQ:
IBB
)
170.20
-3.63 (-2.09%)
Streaming Delayed Price
Updated: 3:52 PM EST, Dec 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about iShares Biotechnology ETF
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
27
28
Next >
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
↗
January 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...
Via
Benzinga
The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award
↗
January 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen...
Via
Benzinga
How Biotech Confirmed A Reversal Pattern in Both Price and Momentum
↗
January 11, 2022
For roughly three months the biotechnology ETF IBB has been trending lower. Though it’s made multiple attempts to clear the 50-Day moving average, it has failed.
Via
Talk Markets
The Daily Biotech Pulse: Illunina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In
↗
January 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo...
Via
Benzinga
Top 10 Investment Themes For 2022
↗
December 25, 2021
What are the investment trends going to look like for 2022?
Via
Talk Markets
Could Greece (GREK) be Waking Up?
↗
January 10, 2022
While the major indices were selling off Monday, GREK held near an important breakout area.
Via
Talk Markets
The Week Ahead In Biotech (Jan 10-15): JPMorgan Healthcare Conference Front And Center, Preannouncements Keep Coming
↗
January 10, 2022
Biotech stocks came under selling pressure along with the broader market, as rate hike fears seized Wall Street. The news flow, however, was scanty. Last week, the Food and Drug...
Via
Benzinga
There Is A Skip In The Song
↗
January 09, 2022
Early January is when we should always be prepared for a skip in the song playing in the market's narrative. The 2022
Via
Talk Markets
The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs
↗
January 07, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name...
Via
Benzinga
ETF Battles: Which Biotech Stock ETF Is The Better Choice? - It's IBB Vs. XBI
↗
December 23, 2021
A biotech clash between the iShares Biotechnology ETF and the SPDR S&P Biotech ETF.
Via
Talk Markets
The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales
↗
January 06, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Illumina Announces Co-Development Partnership With SomaScan For Accelerating...
Via
Benzinga
The Fed Confirms They Were Wrong About Inflation
↗
January 05, 2022
Wednesday’s Fed minutes showed that inflation has further spread in the economy and is going to stick around longer than they had originally anticipated.
Via
Talk Markets
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
↗
January 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,...
Via
Benzinga
What Are Tuesdays Market Outliers Telling Us?
↗
January 04, 2022
Tuesday’s outliers are the Transportation (IYT) and Regional Banking (KRE) sectors.
Via
Talk Markets
The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
↗
January 02, 2022
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. On the regulatory front, the Food And Drug Administration...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
↗
December 31, 2021
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were...
Via
Benzinga
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
↗
December 26, 2021
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating...
Via
Benzinga
Santa Finally Showed Up
↗
December 26, 2021
A “Santa Claus Rally” started this past week. A variety of factors, including lighter volume, less institutional action, end of year bonuses, profit sharing distributions, and less fear about Omicron,...
Via
Talk Markets
Key Areas To Watch This Weekend And Into The New Year
↗
December 24, 2021
With the Holiday weekend upon us let’s take a quick review of Mish’s Economic Modern Family for new trends and ideas as we head into the new year.
Via
Talk Markets
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
↗
December 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...
Via
Benzinga
The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda
↗
December 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With...
Via
Benzinga
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
↗
December 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients...
Via
Benzinga
Is It Time to Start Range Trading?
↗
December 20, 2021
With the major indices having trouble either breaking through the lows or clearing the highs many people are adjusting their trading styles or waiting on the sidelines for better opportunities.
Via
Talk Markets
The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week
↗
December 19, 2021
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also...
Via
Benzinga
Where’s Santa?
↗
December 19, 2021
Investors anticipate the phenomenon that not only happens around most National Holidays, but especially during the Thanksgiving to Christmas season called “The Santa Claus Rally” on Wall Street.
Via
Talk Markets
Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index
↗
December 17, 2021
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:
Via
Benzinga
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
↗
December 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral...
Via
Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
↗
December 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...
Via
Benzinga
Will Wednesdays Momentum Continue or Fade?
↗
December 15, 2021
When it comes to IWM, there is no main resistance level to clear as it’s been rangebound for most of 2021.
Via
Talk Markets
The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO
↗
December 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron...
Via
Benzinga
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
27
28
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today